MedTrace Logo

Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

NCT07328022 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2026-01-08

No results posted yet for this study

Summary

Phase III, multicenter, prospective, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib/betamethasone compared with etoricoxib alone in patients with an acute episode of bursitis, tendinitis, or synovitis affecting the shoulder, elbow, knee, or ankle.

Conditions

  • Bursitis
  • Tendinitis
  • Synovitis

Interventions

DRUG

Fixed Dose Etoricoxib + Betamethasone

One tablet of 90 mg / 0.25 mg a day, for 14 days

DRUG

Monotherapy Etoricoxib

One tablet aog 90 mg a day, for 14 days

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Marco Antonio Cordova Martinez, MD · Unidad de Medicina Especializada SMA SC

  • Pedro Abraham Garza Alvarez, MD · IECSI Clinical Research

  • Juan Luis Torres Mendez, MD · Clinical Research Institute S.C.

  • Yazmin Adriana Guerra Lopez, MD · Centro de Investigación Clínica de México S. de R.L. de C.V

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-14
Primary Completion
2025-08-20
Completion
2025-11-19

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07328022 on ClinicalTrials.gov